Glucose Transporter 1 in Health and Disease

Abstract

Glucose Transporter 1 (GLUT1) is the quintessential facilitator of basal glucose uptake, indispensable for maintaining cellular energy homeostasis, particularly across the blood–brain barrier. Beyond physiological necessity, GLUT1 dysregulation drives a broad pathological spectrum. While genetic haploinsufficiency precipitates severe neurological energy crises like Glut1 deficiency syndrome (Glut1DS), oncogenic networks hyperactivate GLUT1 as the central executor of the Warburg effect to fuel malignant proliferation. Despite its immense therapeutic potential, severe on-target toxicity in normal tissues and adaptive metabolic plasticity remain critical roadblocks to systemic GLUT1 inhibition. This review comprehensively synthesizes GLUT1's multidimensional regulatory networks in health and disease, dissecting how its overexpression fundamentally remodels the tumor microenvironment (TME). We elucidate how GLUT1-driven “metabolic competition” fosters metabolic immune exclusion and drives therapeutic resistance. Furthermore, we map the paradigm shift from traditional systemic blockades to emerging precision interventions. Specifically, we highlight “Trojan horse” glycan-functionalized nanocarriers, targeted protein degradation technologies like PROTACs, and metabolically engineered CAR-T cells. By conceptualizing GLUT1 as the linchpin of the immunosuppressive ecosystem, this work provides a strategic roadmap for precision metabolic immuno-oncology, guiding the development of novel therapies that maximize durable efficacy while minimizing collateral physiological damage.

Keywords

glucose homeostasis / glucose transporter 1 (GLUT1) / tumor microenvironment (TME) / targeted therapy / Warburg effect

References

[1] E. M. Wright, D. D. Loo, and B. A. Hirayama, “Biology of human Sodium Glucose Transporters,” Physiological Reviews 91, no. 2 (2011): 733–794.

[2] R. E. Airley and A. Mobasheri, “Hypoxic Regulation of Glucose Transport, anaerobic Metabolism and Angiogenesis in Cancer: Novel Pathways and Targets for Anticancer Therapeutics,” Chemotherapy 53, no. 4 (2007): 233–256.

[3] E. S. Reckzeh and H. Waldmann, “Small-Molecule Inhibition of Glucose Transporters GLUT-1-4,” Chembiochem 21, no. 1-2 (2020): 45–52.

[4] Y. Liu, X. Li, J. Yang, et al., “Pan-cancer Analysis of SLC2A Family Genes as Prognostic Biomarkers and Therapeutic Targets,” Heliyon 10, no. 8 (2024): e29655.

[5] M. Kawatani and H. Osada, “Small-Molecule Inhibitors of Glucose Transporters,” Vitamins and Hormones 128 (2025): 213–242.

[6] T. Daida, B. C. Shin, C. Cepeda, et al., “Neurodevelopment Is Dependent on Maternal Diet: Placenta and Brain Glucose Transporters GLUT1 and GLUT3,” Nutrients 16, no. 14 (2024): 2363.

[7] J. L. Steiner and C. H. Lang, “Alcohol, Adipose Tissue and Lipid Dysregulation,” Biomolecules 7, no. 1 (2017): 16.

[8] S. S. Im, S. K. Kwon, T. H. Kim, et al., “Regulation of Glucose Transporter Type 4 Isoform Gene Expression in Muscle and Adipocytes,” IUBMB Life 59, no. 3 (2007): 134–145.

[9] C. I. Rivas, F. A. Zúñiga, A. Salas-Burgos, et al., “Vitamin C Transporters,” Journal of Physiology and Biochemistry 64, no. 4 (2008): 357–375.

[10] A. L. Olson and J. E. Pessin, “Structure, Function, and Regulation of the Mammalian Facilitative Glucose Transporter Gene family,” Annual Review of Nutrition 16 (1996): 235–256.

[11] J. Zhang, K. A. Sjøberg, S. Gong, et al., “Endothelial Metabolic Control of Insulin Sensitivity Through Resident Macrophages,” Cell Metabolism 36, no. 11 (2024): 2383–2401.e9.

[12] K. Veys, Z. Fan, M. Ghobrial, et al., “Role of the GLUT1 Glucose Transporter in Postnatal CNS Angiogenesis and Blood-Brain Barrier Integrity,” Circulation Research 127, no. 4 (2020): 466–482.

[13] K. Ding, Z. Zhang, Z. Han, et al., “Liver ALKBH5 Regulates Glucose and Lipid Homeostasis Independently Through GCGR and mTORC1 Signaling,” Science (New York, NY) 387, no. 6737 (2025): eadp4120.

[14] B. Sun, H. Chen, J. Xue, et al., “The Role of GLUT2 in Glucose Metabolism in Multiple Organs and Tissues,” Molecular Biology Reports 50, no. 8 (2023): 6963–6974.

[15] J. Klepper, “Glut1 Deficiency Syndrome: Novel Pathomechanisms, Current Concepts, and Challenges,” Journal of Inherited Metabolic Disease 48, no. 3 (2025): e70044.

[16] E. M. Orsini, S. Roychowdhury, M. Gangadhariah, et al., “TRPV4 Regulates the Macrophage Metabolic Response to Limit Sepsis-Induced Lung Injury,” American Journal of Respiratory Cell and Molecular Biology 70, no. 6 (2024): 457–467.

[17] J. Yang, S. Li, Z. Li, et al., “Targeting YAP1-regulated Glycolysis in Fibroblast-Like Synoviocytes Impairs Macrophage Infiltration to Ameliorate Diabetic Osteoarthritis Progression,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 5 (2024): e2304617.

[18] I. Subudhi, P. Konieczny, A. Prystupa, et al., “Metabolic Coordination Between Skin Epithelium and Type 17 Immunity Sustains Chronic Skin Inflammation,” Immunity 57, no. 7 (2024): 1665–1680.e7.

[19] Y. Li, H. Zhou, X. He, et al., “Impaired Microglial Glycolysis Promotes Inflammatory Responses After Intracerebral Haemorrhage via HK2-Dependent Mitochondrial Dysfunction,” Journal of Advanced Research 73 (2025): 575–591.

[20] S. M. Morrissey, F. Zhang, C. Ding, et al., “Tumor-Derived Exosomes Drive Immunosuppressive Macrophages in a Pre-Metastatic Niche Through Glycolytic Dominant Metabolic Reprogramming,” Cell Metabolism 33, no. 10 (2021): 2040–2058.e10.

[21] J. Q. Xu, Y. L. Fu, J. Zhang, et al., “Targeting Glycolysis in Non-Small Cell Lung Cancer: Promises and Challenges,” Frontiers in Pharmacology 13 (2022): 1037341.

[22] R. J. DeBerardinis and N. S. Chandel, “We Need to Talk About the Warburg Effect,” Nature Metabolism 2, no. 2 (2020): 127–129.

[23] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31–46.

[24] H. J. Yun, M. Li, D. Guo, et al., “AMPK-HIF-1α Signaling Enhances Glucose-Derived De Novo Serine Biosynthesis to Promote Glioblastoma Growth,” Journal of Experimental & Clinical Cancer Research: CR 42, no. 1 (2023): 340.

[25] H. Song, Z. Qiu, Y. Wang, et al., “HIF-1α/YAP Signaling Rewrites Glucose/Iodine Metabolism Program to Promote Papillary Thyroid Cancer Progression,” International Journal of Biological Sciences 19, no. 1 (2023): 225–241.

[26] X. Liu, K. Yamaguchi, K. Takane, et al., “Cancer-associated IDH Mutations Induce Glut1 Expression and Glucose Metabolic Disorders Through a PI3K/Akt/mTORC1-Hif1α Axis,” PLoS ONE 16, no. 9 (2021): e0257090.

[27] C. Sun, Y. Shen, F. Wang, et al., “Sympathetic Nervous System in Tumor Progression and Metabolic Regulation: Mechanisms and Clinical Potential,” Journal of Translational Medicine 23, no. 1 (2025): 836.

[28] L. W. Macharia, W. Muriithi, C. P. Heming, et al., “The Genotypic and Phenotypic Impact of Hypoxia Microenvironment on Glioblastoma Cell Lines,” BMC Cancer 21, no. 1 (2021): 1248.

[29] S. Ito, T. Fukusato, T. Nemoto, et al., “Coexpression of Glucose Transporter 1 and Matrix Metalloproteinase-2 in Human Cancers,” Journal of the National Cancer Institute 94, no. 14 (2002): 1080–1091.

[30] T. Higashi, N. Tamaki, T. Torizuka, et al., “FDG Uptake, GLUT-1 Glucose Transporter and Cellularity in Human Pancreatic Tumors,” Journal of Nuclear Medicine 39, no. 10 (1998): 1727–1735.

[31] X. Lu, J. Liu, L. Feng, et al., “BATF Promotes Tumor Progression and Association With FDG PET-Derived Parameters in Colorectal Cancer,” Journal of Translational Medicine 22, no. 1 (2024): 558.

[32] M. Rodriguez-Zabala, R. Ramakrishnan, K. Reinbach, et al., “Combined GLUT1 and OXPHOS Inhibition Eliminates Acute Myeloid Leukemia Cells by Restraining Their Metabolic Plasticity,” Blood Advances 7, no. 18 (2023): 5382–5395.

[33] Y. Wang, X. Wang, B. Bai, et al., “Targeting Src SH3 Domain-Mediated Glycolysis of HSC Suppresses Transcriptome, Myofibroblastic Activation, and Colorectal Liver Metastasis,” Hepatology (Baltimore, MD) 80, no. 3 (2024): 578–594.

[34] J. Wang, C. Ye, C. Chen, et al., “Glucose Transporter GLUT1 Expression and Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis,” Oncotarget 8, no. 10 (2017): 16875–16886.

[35] M. Yu, H. Yongzhi, S. Chen, et al., “The Prognostic Value of GLUT1 in Cancers: A Systematic Review and Meta-Analysis,” Oncotarget 8, no. 26 (2017): 43356–43367.

[36] C. Pinheiro, V. Miranda-Gonçalves, A. Longatto-Filho, et al., “The Metabolic Microenvironment of Melanomas: Prognostic Value of MCT1 and MCT4,” Cell Cycle (Georgetown, Tex) 15, no. 11 (2016): 1462–1470.

[37] A. Ghosh, A. K. Ghosh, A. Zaman, et al., “Metformin-Loaded Hyaluronic Acid-Derived Carbon Dots for Targeted Therapy Against Hepatocellular Carcinoma by Glutamine Metabolic Reprogramming,” Molecular Pharmaceutics 20, no. 12 (2023): 6391–6406.

[38] T. Huang, Q. You, J. Liu, et al., “WTAP Mediated m6A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 12, no. 33 (2025): e06529.

[39] Y. Guo, C. Luo, Y. Sun, et al., “Inhibition of Mitochondrial Fusion via SIRT1/PDK2/PARL Axis Breaks Mitochondrial Metabolic Plasticity and Sensitizes Cancer Cells to Glucose Restriction Therapy,” Biomedicine & Pharmacotherapy 166 (2023): 115342.

[40] Y. Zhang, Y. Ren, H. Xu, et al., “Cascade-Responsive 2-DG Nanocapsules Encapsulate aV-siCPT1C Conjugates to Inhibit Glioblastoma Through Multiple Inhibition of Energy Metabolism,” ACS Applied Materials & Interfaces 15, no. 8 (2023): 10356–10370.

[41] L. Shen, M. Chen, Y. Su, et al., “NIR-II Imaging for Tracking the Spatiotemporal Immune Microenvironment in Atherosclerotic Plaques,” ACS Nano 18, no. 50 (2024): 34171–34185.

[42] L. J. Elsas and N. Longo, “Glucose Transporters,” Annual Review of Medicine 43 (1992): 377–393.

[43] C. Zhang, L. Gu, H. Xie, et al., “Glucose Transport, Transporters and Metabolism in Diabetic Retinopathy,” Biochimica et Biophysica Acta Molecular Basis of Disease 1870, no. 3 (2024): 166995.

[44] L. Bertrand, J. Auquier, E. Renguet, et al., “Glucose Transporters in Cardiovascular System in Health and Disease,” Pflugers Archiv: European Journal of Physiology 472, no. 9 (2020): 1385–1399.

[45] M. Mueckler, “Facilitative Glucose Transporters,” European Journal of Biochemistry 219, no. 3 (1994): 713–725.

[46] B. Thorens and M. Mueckler, “Glucose Transporters in the 21st Century,” American Journal of Physiology Endocrinology and Metabolism 298, no. 2 (2010): E141–E145.

[47] F. Assimacopoulos-Jeannet, I. Cusin, R. M. Greco-Perotto, et al., “Glucose Transporters: Structure, Function, and Regulation,” Biochimie 73, no. 1 (1991): 67–70.

[48] A. So and B. Thorens, “Uric Acid Transport and Disease,” Journal of Clinical Investigation 120, no. 6 (2010): 1791–1799.

[49] D. Deng, C. Xu, P. Sun, et al., “Crystal Structure of the human Glucose Transporter GLUT1,” Nature 510, no. 7503 (2014): 121–125.

[50] T. Galochkina, F. Ng, M. Chong, L. Challali, et al., “New Insights Into GluT1 Mechanics During Glucose Transfer,” Scientific Reports 9, no. 1 (2019): 998.

[51] D. Wang, T. Sands, and M. Tang, “Glucose Transporter Type 1 Deficiency Syndrome,” in GeneReviews(®), ed. M. P. Adam, S. Bick, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, and A. Amemiya (University of Washington). Copyright © 1993–2026, University of Washington, Seattle. GeneReviews Is a Registered Trademark of the University of Washington, Seattle All rights reserved; 1993.

[52] C. G. Ardanaz, A. de la Cruz, P. S. Minhas, et al., “Astrocytic GLUT1 Reduction Paradoxically Improves central and Peripheral Glucose Homeostasis,” Science Advances 10, no. 42 (2024): eadp1115.

[53] M. Güemes, S. A. Rahman, and K. Hussain, “What Is a Normal Blood Glucose?,” Archives of Disease in Childhood 101, no. 6 (2016): 569–574.

[54] N. P. Joshi, A. R. Mane, A. S. Sahay, et al., “Role of Placental Glucose Transporters in Determining Fetal Growth,” Reproductive Sciences (Thousand Oaks, CA) 29, no. 10 (2022): 2744–2759.

[55] K. Cai, S. Chen, C. Zhu, et al., “FOXD1 Facilitates Pancreatic Cancer Cell Proliferation, Invasion, and Metastasis by Regulating GLUT1-Mediated Aerobic Glycolysis,” Cell Death & Disease 13, no. 9 (2022): 765.

[56] Z. Zhou, Y. Li, S. Chen, et al., “GLUT1 promotes Cell Proliferation via Binds and Stabilizes Phosphorylated EGFR in Lung Adenocarcinoma,” Cell Communication and Signaling 22, no. 1 (2024): 303.

[57] F. Chen, N. Wang, J. Liao, et al., “Esculetin Rebalances M1/M2 Macrophage Polarization to Treat Sepsis-Induced Acute Lung Injury Through Regulating Metabolic Reprogramming,” Journal of Cellular and Molecular Medicine 28, no. 21 (2024): e70178.

[58] R. Chen, S. Zheng, X. Zhao, et al., “Metabolic Reprogramming of Macrophages by a Nano-Sized Opsonization Strategy to Restore M1/M2 Balance for Osteoarthritis Therapy,” Journal of Controlled Release 380 (2025): 469–489.

[59] T. A. Phu, M. Ng, N. K. Vu, et al., “ApoE Expression in Macrophages Communicates Immunometabolic Signaling That Controls Hyperlipidemia-Driven Hematopoiesis & Inflammation via Extracellular Vesicles,” Journal of Extracellular Vesicles 12, no. 8 (2023): e12345.

[60] A. De Leo, A. Ugolini, X. Yu, et al., “Glucose-Driven Histone Lactylation Promotes the Immunosuppressive Activity of Monocyte-Derived Macrophages in Glioblastoma,” Immunity 57, no. 5 (2024): 1105–1123.e8.

[61] S. Verma, S. Budhu, I. Serganova, et al., “Pharmacologic LDH Inhibition Redirects Intratumoral Glucose Uptake and Improves Antitumor Immunity in Solid Tumor Models,” Journal of Clinical Investigation 134, no. 17 (2024): e177606.

[62] Q. Wang, W. Lin, K. Lei, et al., “Hyperglycemia-Enhanced Neutrophil Extracellular Traps Drive Mucosal Immunopathology at the Oral Barrier,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 47 (2024): e2407346.

[63] A. Gallerand, B. Dolfi, M. I. Stunault, et al., “Glucose Metabolism Controls Monocyte Homeostasis and Migration but Has no Impact on Atherosclerosis Development in Mice,” Nature Communications 15, no. 1 (2024): 9027.

[64] X. Li, M. Yang, T. Wang, et al., “GLUT1 and GLUT3 in Brain Glucose Metabolism: Mechanisms, Regulation, and Implications for Metabolic Disorders,” Metabolic Brain Disease 41, no. 1 (2025): 3.

[65] S. J. Kierans, R. R. Fagundes, M. I. Malkov, et al., “Hypoxia Induces a Glycolytic Complex in Intestinal Epithelial Cells Independent of HIF-1-Driven Glycolytic Gene Expression,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 35 (2023): e2208117120.

[66] L. Ouyang, X. Gao, R. Yang, et al., “SHP2 Regulates the HIF-1 Signaling Pathway in the Decidual Human Endometrial Stromal Cells†,” Biology of Reproduction 112, no. 4 (2025): 743–753.

[67] C. Li, C. Fu, W. Zhou, et al., “Lactylation Modification of HIF-1α Enhances Its Stability by Blocking VHL Recognition,” Cell Communication and Signaling 23, no. 1 (2025): 364.

[68] Z. Wang, Y. Huang, Y. Zhang, et al., “Knockdown of SESN2 Exacerbates Cerebral Ischemia-Reperfusion Injury through Enhancing Glycolysis via the mTOR/HIF-1α Pathway,” CNS Neuroscience & Therapeutics 31, no. 3 (2025): e70314.

[69] Y. Chen, X. Bai, J. Chen, et al., “Pyruvate Kinase M2 Regulates Kidney Fibrosis Through Pericyte Glycolysis During the Progression From Acute Kidney Injury to Chronic Kidney Disease,” Cell Proliferation 57, no. 2 (2024): e13548.

[70] R. Tsutsumi, B. Ueberheide, F. X. Liang, et al., “Endocytic Vesicles Act as Vehicles for Glucose Uptake in Response to Growth Factor Stimulation,” Nature Communications 15, no. 1 (2024): 2843.

[71] S. J. Qualls-Histed, C. P. Nielsen, and J. A. MacGurn, “Lysosomal Trafficking of the Glucose Transporter GLUT1 Requires Sequential Regulation by TXNIP and Ubiquitin,” Iscience 26, no. 3 (2023): 106150.

[72] C. E. Villanueva and B. Hagenbuch, “Palmitoylation of Solute Carriers,” Biochemical Pharmacology 215 (2023): 115695.

[73] K. Rump and M. Adamzik, “Aquaporins in Sepsis- An Update,” Frontiers in Immunology 15 (2024): 1495206.

[74] R. B. Colombo, C. Maxit, D. Martinelli, et al., “PURA and GLUT1: Sweet Partners for Brain Health,” Biochimica et Biophysica Acta Molecular Basis of Disease 1870, no. 6 (2024): 167261.

[75] I. Tamura, A. Shiroshita, T. Fujimura, et al., “Glucose and Lipid Metabolisms in Human Endometrial Stromal Cells During Decidualization,” Endocrine Journal 70, no. 5 (2023): 465–472.

[76] S. Yoshino, E. Ishida, K. Horiguchi, et al., “Mixed-Lineage Leukaemia Gene Regulates Glucose-Sensitive Gene Expression and Insulin Secretion in Pancreatic Beta Cells,” International Journal of Molecular Sciences 25, no. 9 (2024): 4704.

[77] X. Wang, X. Han, J. Ma, et al., “5-hydroxymethylfurfural Attenuates Osteoarthritis by Upregulating of Glucose Metabolism in Chondrocytes,” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 139 (2025): 156499.

[78] M. S. Byers, C. Howard, and X. Wang, “Avian and Mammalian Facilitative Glucose Transporters,” Microarrays (Basel, Switzerland) 6, no. 2 (2017): 7.

[79] F. Wang, Y. Hu, H. Wang, et al., “LncRNA FTO-IT1 Promotes Glycolysis and Progression of Hepatocellular Carcinoma Through Modulating FTO-Mediated N6-Methyladenosine Modification on GLUT1 and PKM2,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 267.

[80] E. Majewska, Z. Zdort, A. Ochocka, et al., “Myoclonus in Pediatric Metabolic Diseases: Clinical Spectrum, Mechanisms, and Treatable Causes-A Systematic Review,” Metabolites 16, no. 2 (2026): 98.

[81] M. Corradini, M. P. Zanaboni, C. Varesio, et al., “GLUT1DS Focus on Dysarthria,” European Journal of Paediatric Neurology 51 (2024): 62–70.

[82] S. Olivotto, A. Freddi, and R. Previtali, “Stroke and Stroke-Like Episodes: Recurrent Manifestations in GLUT1 Deficiency Syndrome,” Pediatric Neurology 157 (2024): 118–126.

[83] D. Yavorov-Dayliev, F. I. Milagro, J. Ayo, et al., “Glucose-Lowering Effects of a Synbiotic Combination Containing Pediococcus acidilactici in C. elegans and Mice,” Diabetologia 66, no. 11 (2023): 2117–2138.

[84] Y. R. Zhang, S. M. Liu, Y. Chen, et al., “Intermedin Alleviates Diabetic Vascular Calcification by Inhibiting GLUT1 Through Activation of the cAMP/PKA Signaling Pathway,” Atherosclerosis 385 (2023): 117342.

[85] Y. Nakayama, S. Kobayashi, A. Masihuddin, et al., “Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes,” Circulation Research 135, no. 3 (2024): 416–433.

[86] B. Chen, J. Zou, L. Xie, et al., “WNT-inhibitory Factor 1-Mediated Glycolysis Protects Photoreceptor Cells in Diabetic Retinopathy,” Journal of Translational Medicine 22, no. 1 (2024): 245.

[87] K. Sun, Y. Chen, S. Zheng, et al., “Genipin Ameliorates Diabetic Retinopathy via the HIF-1α and AGEs-RAGE Pathways,” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 129 (2024): 155596.

[88] Q. Zhang, X. Yuan, X. Luan, et al., “GLUT1 exacerbates Trophoblast Ferroptosis by Modulating AMPK/ACC Mediated Lipid Metabolism and Promotes Gestational Diabetes Mellitus Associated Fetal Growth Restriction,” Molecular Medicine (Cambridge, MA) 30, no. 1 (2024): 257.

[89] S. Raut, A. Bhalerao, M. Powers, et al., “Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview,” Cells 12, no. 16 (2023): 2019.

[90] M. Leclerc, C. Tremblay, P. Bourassa, et al., “Lower GLUT1 and Unchanged MCT1 in Alzheimer's Disease Cerebrovasculature,” Journal of Cerebral Blood Flow and Metabolism 44, no. 8 (2024): 1417–1432.

[91] S. Fakorede, T. A. Sodiq, A. O. Ajagbe, et al., “Interplay of Glut1 Alteration and Alzheimer's Disease: A Narrative Review on Glucose Transport and Energy Metabolism,” Journal of Alzheimer's Disease 108, no. 2 (2025): 470–486.

[92] L. Wang, G. L. Curran, R. Zhong, et al., “Amyloid Beta Peptides Inhibit Glucose Transport at the Blood-Brain Barrier by Disrupting the Insulin-AKT Pathway,” Journal of Cerebral Blood Flow and Metabolism 45, no. 10 (2025): 1961–1979.

[93] R. A. Fontanella, P. Ghosh, A. Pesapane, et al., “Tirzepatide Prevents Neurodegeneration Through Multiple Molecular Pathways,” Journal of Translational Medicine 22, no. 1 (2024): 114.

[94] G. Hurtado-Alvarado, E. Soto-Tinoco, E. Santacruz-Martínez, et al., “Suprachiasmatic Nucleus Promotes Hyperglycemia Induced by Sleep Delay,” Current Biology 33, no. 20 (2023): 4343–4352.e4.

[95] B. Miao, M. S. Mohiuddin, R. Barua, et al., “Glucose Transporter 1 Is Essential to Maintain Brain Endothelial Cell Homeostasis Under Hyperglycemia Condition,” American Journal of Physiology Cell Physiology 329, no. 2 (2025): C341–c354.

[96] P. B. Ancey, C. Contat, and E. Meylan, “Glucose Transporters in Cancer—From Tumor Cells to the Tumor Microenvironment,” FEBS Journal 285, no. 16 (2018): 2926–2943.

[97] S. Roy, A. M. Leidal, J. Ye, et al., “Autophagy-Dependent Shuttling of TBC1D5 Controls Plasma Membrane Translocation of GLUT1 and Glucose Uptake,” Molecular Cell 67, no. 1 (2017): 84–95.e5.

[98] K. Offermans, J. C. Jenniskens, C. C. Simons, et al., “Association Between Individual Warburg-Related Proteins and Prognosis in Colorectal Cancer,” Journal of Pathology Clinical Research 11, no. 2 (2025): e70016.

[99] X. Q. Huang, X. Chen, X. X. Xie, et al., “Co-expression of CD147 and GLUT-1 Indicates Radiation Resistance and Poor Prognosis in Cervical Squamous Cell Carcinoma,” International Journal of Clinical and Experimental Pathology 7, no. 4 (2014): 1651–1666.

[100] H. Sawayama, Y. Ogata, T. Ishimoto, et al., “Glucose Transporter 1 Regulates the Proliferation and Cisplatin Sensitivity of Esophageal Cancer,” Cancer Science 110, no. 5 (2019): 1705–1714.

[101] Y. Li, S. Tang, X. Shi, et al., “Metabolic Classification Suggests the GLUT1/ALDOB/G6PD Axis as a Therapeutic Target in Chemotherapy-Resistant Pancreatic Cancer,” Cell Reports Medicine 4, no. 9 (2023): 101162.

[102] Y. Liu, X. Zhang, F. Cheng, et al., “Xanthatin Induce DDP-Resistance Lung Cancer Cells Apoptosis Through Regulation of GLUT1 Mediated ROS Accumulation,” Drug Development Research 84, no. 6 (2023): 1266–1278.

[103] F. Y. Chung, M. Y. Huang, C. S. Yeh, et al., “GLUT1 gene Is a Potential Hypoxic Marker in Colorectal Cancer Patients,” BMC Cancer 9 (2009): 241.

[104] Q. Q. Li, Y. P. Sun, C. P. Ruan, et al., “Cellular Prion Protein Promotes Glucose Uptake Through the Fyn-HIF-2α-Glut1 Pathway to Support Colorectal Cancer Cell Survival,” Cancer Science 102, no. 2 (2011): 400–406.

[105] J. Kokeza, A. Strikic, M. Ogorevc, et al., “The Effect of GLUT1 and HIF-1α Expressions on Glucose Uptake and Patient Survival in Non-Small-Cell Lung Carcinoma,” International Journal of Molecular Sciences 24, no. 13 (2023): 10575.

[106] L. Chen, L. Zhang, H. He, et al., “Ubiquitin-Specific Protease 54 Regulates GLUT1-mediated Aerobic Glycolysis to Inhibit Lung Adenocarcinoma Progression by Modifying p53 Degradation,” Oncogene 43, no. 26 (2024): 2025–2037.

[107] G. Wu, C. Li, J. Tao, et al., “FSH Mediates Estradiol Synthesis in Hypoxic Granulosa Cells by Activating Glycolytic Metabolism Through the HIF-1α-AMPK-GLUT1 Signaling Pathway,” Journal of Biological Chemistry 298, no. 5 (2022): 101830.

[108] Z. Jing, Q. Liu, X. He, et al., “NCAPD3 enhances Warburg Effect Through c-myc and E2F1 and Promotes the Occurrence and Progression of Colorectal Cancer,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 198.

[109] Z. Liu, M. He, Z. Yu, et al., “TIFA Enhances Glycolysis Through E2F1 and Promotes the Progression of Glioma,” Cellular Signalling 125 (2025): 111498.

[110] P. Wang, J. Sun, C. Sun, et al., “BTF3 Promotes Proliferation and Glycolysis in Hepatocellular Carcinoma by Regulating GLUT1,” Cancer Biology & Therapy 24, no. 1 (2023): 2225884.

[111] S. Wei, Q. Fan, and L. Yang, “Promotion of Glycolysis by HOTAIR Through GLUT1 Upregulation via mTOR Signaling,” Oncology Reports 38, no. 3 (2017): 1902–1908.

[112] Z. Zhao, L. Wang, E. Bartom, et al., “β-Catenin/Tcf7l2-dependent Transcriptional Regulation of GLUT1 Gene Expression by Zic family Proteins in Colon Cancer,” Science Advances 5, no. 7 (2019): eaax0698.

[113] X. Ding, J. Liu, T. Liu, et al., “miR-148b Inhibits Glycolysis in Gastric Cancer Through Targeting SLC2A1,” Cancer Medicine 6, no. 6 (2017): 1301–1310.

[114] D. Zhou, L. Jiang, and L. Jin, “Glucose Transporter-1 Cooperating With AKT Signaling Promote Gastric Cancer Progression,” Cancer Management and Research 12 (2020): 4151–4160.

[115] C. Pan, Q. Liu, and X. Wu, “HIF1α/miR-520a-3p/AKT1/mTOR Feedback Promotes the Proliferation and Glycolysis of Gastric Cancer Cells,” Cancer Management and Research 11 (2019): 10145–10156.

[116] H. Chen, S. Gao, W. Liu, et al., “RNA N(6)-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the M(6)A-GLUT1-mTORC1 Axis and Is a Therapeutic Target,” Gastroenterology 160, no. 4 (2021): 1284–1300.e16.

[117] C. Shen, B. Xuan, and T. Yan, “m(6)A-Dependent Glycolysis Enhances Colorectal Cancer Progression,” Molecular Cancer 19, no. 1 (2020): 72.

[118] B. Li, H. Kang, Y. Xiao, et al., “LncRNA GAL Promotes Colorectal Cancer Liver Metastasis Through Stabilizing GLUT1,” Oncogene 41, no. 13 (2022): 1882–1894.

[119] D. Zhou, Y. Yao, L. Zong, et al., “TBK1 Facilitates GLUT1-Dependent Glucose Consumption by Suppressing mTORC1 Signaling in Colorectal Cancer Progression,” International Journal of Biological Sciences 18, no. 8 (2022): 3374–3389.

[120] L. Wu, Y. Jin, X. Zhao, et al., “Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing via TNF-α,” Cell Metabolism 35, no. 9 (2023): 1580–1596.e9.

[121] W. Hu, F. Li, Y. Liang, et al., “Glut3 Overexpression Improves Environmental Glucose Uptake and Antitumor Efficacy of CAR-T Cells in Solid Tumors,” Journal for Immunotherapy of Cancer 13, no. 1 (2025): e010540.

[122] J. A. Guerrero, D. D. Klysz, Y. Chen, et al., “GLUT1 Overexpression in CAR-T Cells Induces Metabolic Reprogramming and Enhances Potency,” Nature Communications 15, no. 1 (2024): 8658.

[123] R. S. Haber, A. Rathan, K. R. Weiser, et al., “GLUT1 Glucose Transporter Expression in Colorectal Carcinoma: A Marker for Poor Prognosis,” Cancer 83, no. 1 (1998): 34–40.

[124] Y. J. Jun, S. M. Jang, H. L. Han, et al., “Clinicopathologic Significance of GLUT1 Expression and Its Correlation With Apaf-1 in Colorectal Adenocarcinomas,” World Journal of Gastroenterology 17, no. 14 (2011): 1866–1873.

[125] M. Sakashita, N. Aoyama, R. Minami, et al., “Glut1 Expression in T1 and T2 Stage Colorectal Carcinomas: Its Relationship to Clinicopathological Features,” European Journal of Cancer (Oxford, England: 1990) 37, no. 2 (2001): 204–209.

[126] K. Offermans, J. C. Jenniskens, C. C. Simons, et al., “Expression of Proteins Associated With the Warburg-Effect and Survival in Colorectal Cancer,” Journal of Pathology Clinical Research 8, no. 2 (2022): 169–180.

[127] Y. Geng, X. Zheng, D. Zhang, et al., “CircHIF1A Induces Cetuximab Resistance in Colorectal Cancer by Promoting HIF1α-Mediated Glycometabolism Alteration,” Biology Direct 19, no. 1 (2024): 36.

[128] C. Li, Q. Chen, Y. Zhou, et al., “S100A2 promotes Glycolysis and Proliferation via GLUT1 Regulation in Colorectal Cancer,” FASEB Journal 34, no. 10 (2020): 13333–13344.

[129] J. Wang, M. Zhu, J. Zhu, et al., “HES1 Promotes Aerobic Glycolysis and Cancer Progression of Colorectal Cancer via IGF2BP2-Mediated GLUT1 m6A Modification,” Cell Death Discovery 9, no. 1 (2023): 411.

[130] S. Huang, X. Wang, Y. Zhu, et al., “SOX2 promotes Vasculogenic Mimicry by Accelerating Glycolysis via the lncRNA AC005392.2-GLUT1 Axis in Colorectal Cancer,” Cell Death & Disease 14, no. 12 (2023): 791.

[131] M. Hayashi, K. Nakamura, S. Harada, et al., “GLUT1 Inhibition by BAY-876 Induces Metabolic Changes and Cell Death in Human Colorectal Cancer Cells,” BMC Cancer 25, no. 1 (2025): 716.

[132] Q. Zhang, Y. Qin, X. Sun, et al., “Sodium Butyrate Blocks the Growth of Colorectal Cancer by Inhibiting the Aerobic Glycolysis Mediated by SIRT4/HIF-1α,” Chemico-Biological Interactions 403 (2024): 111227.

[133] F. Martel, M. Guedes, and E. Keating, “Effect of Polyphenols on Glucose and Lactate Transport by Breast Cancer Cells,” Breast Cancer Research and Treatment 157, no. 1 (2016): 1–11.

[134] X. Zhang, X. Pang, Z. Zhang, et al., “Co-expression and Prognosis Analyses of GLUT1-4 and RB1 in Breast Cancer,” BMC Cancer 21, no. 1 (2021): 1026.

[135] Q. Wu, W. Ba-Alawi, G. Deblois, et al., “GLUT1 Inhibition Blocks Growth of RB1-Positive Triple Negative Breast Cancer,” Nature Communications 11, no. 1 (2020): 4205.

[136] O. Okcu, B. Sen, C. Ozturk, et al., “GLUT-1 Expression in Breast Cancer,” Turkish Journal of Pathology 38, no. 2 (2022): 114–121.

[137] M. Hanbazazh, A. Samman, S. Samargandy, et al., “Prognostic Value of Glucose Transporter Proteins-1 (GLUT1) in Breast Carcinoma,” Libyan Journal of Medicine 18, no. 1 (2023): 2283953.

[138] Y. Deng, J. Zou, T. Deng, et al., “Clinicopathological and Prognostic Significance of GLUT1 in Breast Cancer: A Meta-Analysis,” Medicine 97, no. 48 (2018): e12961.

[139] D. Williams, E. Hargrove-Wiley, W. Bindeman, et al., “Type II Interleukin-4 Receptor Activation in Basal Breast Cancer Cells Promotes Tumor Progression via Metabolic and Epigenetic Modulation,” International Journal of Molecular Sciences 25, no. 9 (2024): 4647.

[140] D. Rivenzon-Segal, S. Boldin-Adamsky, D. Seger, et al., “Glycolysis and Glucose Transporter 1 as Markers of Response to Hormonal Therapy in Breast Cancer,” International Journal of Cancer 107, no. 2 (2003): 177–182.

[141] B. Hao, H. Dong, R. Xiong, et al., “Identification of SLC2A1 as a Predictive Biomarker for Survival and Response to Immunotherapy in Lung Squamous Cell Carcinoma,” Computers in Biology and Medicine 171 (2024): 108183.

[142] G. Zhang, R. Dong, D. Kong, et al., “The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis,” Anti-Cancer Agents in Medicinal Chemistry 22, no. 2 (2022): 223–238.

[143] P. B. Ancey, C. Contat, G. Boivin, et al., “GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy,” Cancer Research 81, no. 9 (2021): 2345–2357.

[144] H. Fukuda, K. Arai, H. Mizuno, et al., “Molecular Subtypes of Lung Adenocarcinoma Present Distinct Immune Tumor Microenvironments,” Cancer Science 115, no. 6 (2024): 1763–1777.

[145] E. Smolle, P. Leko, E. Stacher-Priehse, et al., “Distribution and Prognostic Significance of Gluconeogenesis and Glycolysis in Lung Cancer,” Molecular Oncology 14, no. 11 (2020): 2853–2867.

[146] Y. X. Zhou, K. M. Zhou, Q. Liu, et al., “The Effect of Glut1 and c-myc on Prognosis in Esophageal Squamous Cell Carcinoma of Kazakh and Han Patients,” Future Oncology (London, England) 14, no. 18 (2018): 1801–1815.

[147] H. Kato, J. Takita, T. Miyazaki, et al., “Glut-1 Glucose Transporter Expression in Esophageal Squamous Cell Carcinoma Is Associated With Tumor Aggressiveness,” AntiCancer Research 22, no. 5 (2002): 2635–2639.

[148] T. Tohma, S. Okazumi, H. Makino, et al., “Overexpression of Glucose Transporter 1 in Esophageal Squamous Cell Carcinomas: A Marker for Poor Prognosis,” Diseases of the Esophagus 18, no. 3 (2005): 185–189.

[149] H. Sawayama, T. Ishimoto, M. Watanabe, et al., “High Expression of Glucose Transporter 1 on Primary Lesions of Esophageal Squamous Cell Carcinoma Is Associated With Hematogenous Recurrence,” Annals of Surgical Oncology 21, no. 5 (2014): 1756–1762.

[150] X. Sui, H. Zhou, and T. Wang, “GLUT1 maintains Esophageal Cancer Stem Cell-Like Characteristics by Inhibiting Autophagy-Dependent Ferroptosis via EGFR,” Experimental Cell Research 449, no. 2 (2025): 114600.

[151] M. Kobayashi, H. Kaida, A. Kawahara, et al., “The Relationship Between GLUT-1 and Vascular Endothelial Growth Factor Expression and 18F-FDG Uptake in Esophageal Squamous Cell Cancer Patients,” Clinical Nuclear Medicine 37, no. 5 (2012): 447–452.

[152] K. Ahopelto, A. Laitinen, J. Hagström, et al., “Transketolase-Like Protein 1 and Glucose Transporter 1 in Gastric Cancer,” Oncology 98, no. 9 (2020): 643–652.

[153] K. W. Min, D. H. Kim, B. K. Son, et al., “High SLC2A1 Expression Associated With Suppressing CD8 T Cells and B Cells Promoted Cancer Survival in Gastric Cancer,” PLoS ONE 16, no. 3 (2021): e0245075.

[154] F. Berlth, S. Mönig, B. Pinther, et al., “Both GLUT-1 and GLUT-14 Are Independent Prognostic Factors in Gastric Adenocarcinoma,” Annals of Surgical Oncology 22, no. 3 (2015): S822–S831.

[155] J. Tao, Y. Zhang, and T. Wang, “Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review,” Iranian Journal of Public Health 49, no. 11 (2020): 2044–2053.

[156] X. Chen, P. Lu, S. Zhou, et al., “Predictive Value of Glucose Transporter-1 and Glucose Transporter-3 for Survival of Cancer Patients: A Meta-Analysis,” Oncotarget 8, no. 8 (2017): 13206–13213.

[157] K. Reinicke, P. Sotomayor, P. Cisterna, et al., “Cellular Distribution of Glut-1 and Glut-5 in Benign and Malignant human Prostate Tissue,” Journal of Cellular Biochemistry 113, no. 2 (2012): 553–562.

[158] X. Wang, L. Zhou, L. Qi, et al., “High GLUT1 Membrane Expression and Low PSMA Membrane Expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the Prostate,” Prostate Cancer and Prostatic Diseases 27, no. 4 (2024): 720–727.

[159] E. Luczynska, A. Gasinska, and W. Wilk, “Expression of Ki-67 (MIB-1) and GLUT-1 Proteins in Non-Advanced Prostatic Cancer,” Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists 63, no. 4 (2012): 272–277.

[160] H. Xiao, J. Wang, W. Yan, et al., “GLUT1 Regulates Cell Glycolysis and Proliferation in Prostate Cancer,” Prostate 78, no. 2 (2018): 86–94.

[161] A. Gasinska, J. Jaszczynski, U. Rychlik, et al., “Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy,” Pathology Oncology Research: POR 26, no. 2 (2020): 1049–1056.

[162] P. Gonzalez-Menendez, D. Hevia, R. Alonso-Arias, et al., “GLUT1 Protects Prostate Cancer Cells From Glucose Deprivation-Induced Oxidative Stress,” Redox Biology 17 (2018): 112–127.

[163] A. Cannistraci, P. Hascoet, A. Ali, et al., “MiR-378a Inhibits Glucose Metabolism by Suppressing GLUT1 in Prostate Cancer,” Oncogene 41, no. 10 (2022): 1445–1455.

[164] C. V. Vaz, M. G. Alves, R. Marques, et al., “Androgen-responsive and Nonresponsive Prostate Cancer Cells Present a Distinct Glycolytic Metabolism Profile,” International Journal of Biochemistry & Cell Biology 44, no. 11 (2012): 2077–2084.

[165] Y. Liao, Z. Guo, X. Xia, et al., “Inhibition of EGFR Signaling With Spautin-1 Represents a Novel Therapeutics for Prostate Cancer,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 157.

[166] J. Chen, L. Cao, Z. Li, et al., “SIRT1 promotes GLUT1 Expression and Bladder Cancer Progression via Regulation of Glucose Uptake,” Human Cell 32, no. 2 (2019): 193–201.

[167] V. Palit, R. M. Phillips, R. Puri, et al., “Expression of HIF-1alpha and Glut-1 in Human Bladder Cancer,” Oncology Reports 14, no. 4 (2005): 909–913.

[168] O. Stakhovskyi, N. Kobyliak, O. Voylenko, et al., “Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis,” Cells 11, no. 11 (2022): 1802.

[169] F. Massari, C. Ciccarese, M. Santoni, et al., “Metabolic Phenotype of Bladder Cancer,” Cancer Treatment Reviews 45 (2016): 46–57.

[170] X. Wang, H. He, W. Rui, et al., “TRIM38 triggers the Uniquitination and Degradation of Glucose Transporter Type 1 (GLUT1) to Restrict Tumor Progression in Bladder Cancer,” Journal of Translational Medicine 19, no. 1 (2021): 508.

[171] G. Xu, S. Pan, Z. Zhu, et al., “Overexpression of miR-340 Inhibits Cell Proliferation and Induces Apoptosis of human Bladder Cancer via Targeting Glut-1,” BMC Urology 21, no. 1 (2021): 168.

[172] H. L. Chen, H. Y. OuYang, Y. Le, et al., “Aberrant MCT4 and GLUT1 Expression Is Correlated With Early Recurrence and Poor Prognosis of Hepatocellular Carcinoma After Hepatectomy,” Cancer Medicine 7, no. 11 (2018): 5339–5350.

[173] A. P. Alves, A. C. Mamede, M. G. Alves, et al., “Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment?,” Current Cancer Drug Targets 19, no. 1 (2019): 26–40.

[174] L. Wang, Z. Zhu, Q. Liang, et al., “A Novel Small Molecule Glycolysis Inhibitor WZ35 Exerts Anti-Cancer Effect via Metabolic Reprogramming,” Journal of Translational Medicine 20, no. 1 (2022): 530.

[175] Q. Yin, Y. Yao, J. Ni, et al., “DLAT Activates EMT to Promote HCC Metastasis by Regulating GLUT1-Mediated Aerobic Glycolysis,” Molecular Medicine (Cambridge, Mass) 31, no. 1 (2025): 71.

[176] Y. Li, Z. Song, Q. Han, et al., “Targeted Inhibition of STAT3 Induces Immunogenic Cell Death of Hepatocellular Carcinoma Cells via Glycolysis,” Molecular Oncology 16, no. 15 (2022): 2861–2880.

[177] M. A. Reyna-Hernández, L. D. C. Alarcón-Romero, and J. Ortiz-Ortiz, “GLUT1, LDHA, and MCT4 Expression Is Deregulated in Cervical Cancer and Precursor Lesions,” Journal of Histochemistry and Cytochemistry 70, no. 6 (2022): 437–446.

[178] S. Y. Tong, J. M. Lee, K. D. Ki, et al., “Correlation Between FDG Uptake by PET/CT and the Expressions of Glucose Transporter Type 1 and Hexokinase II in Cervical Cancer,” International Journal of Gynecological Cancer 22, no. 4 (2012): 654–658.

[179] B. H. Kim and J. H. Chang, “Differential Effect of GLUT1 Overexpression on Survival and Tumor Immune Microenvironment of human Papilloma Virus Type 16-Positive and -Negative Cervical Cancer,” Scientific Reports 9, no. 1 (2019): 13301.

[180] R. Airley, J. Loncaster, S. Davidson, et al., “Glucose Transporter Glut-1 Expression Correlates With Tumor Hypoxia and Predicts Metastasis-Free Survival in Advanced Carcinoma of the cervix,” Clinical Cancer Research 7, no. 4 (2001): 928–934.

[181] H. C. Sun, Z. J. Qiu, J. Liu, et al., “Expression of Hypoxia-Inducible Factor-1 Alpha and Associated Proteins in Pancreatic Ductal Adenocarcinoma and Their Impact on Prognosis,” International Journal of Oncology 30, no. 6 (2007): 1359–1367.

[182] M. Achalandabaso Boira, M. Di Martino, C. Gordillo, et al., “GLUT-1 as a Predictor of Worse Prognosis in Pancreatic Adenocarcinoma: Immunohistochemistry Study Showing the Correlation Between Expression and Survival,” BMC Cancer 20, no. 1 (2020): 909.

[183] A. Kumari, A. Jha, A. Tiwari, et al., “Role and Regulation of GLUT1/3 During Oral Cancer Progression and Therapy Resistance,” Archives of Oral Biology 150 (2023): 105688.

[184] C. Cheng, J. Tu, Z. Hu, et al., “SREBP2/Rab11s/GLUT1/6 network Regulates Proliferation and Migration of Glioblastoma,” Pathology, Research and Practice 240 (2022): 154176.

[185] M. G. Bredell, J. Ernst, I. El-Kochairi, et al., “Current Relevance of Hypoxia in Head and Neck Cancer,” Oncotarget 7, no. 31 (2016): 50781–50804.

[186] H. L. Penny, J. L. Sieow, S. Y. Gun, et al., “Targeting Glycolysis in Macrophages Confers Protection against Pancreatic Ductal Adenocarcinoma,” International Journal of Molecular Sciences 22, no. 12 (2021): 6350.

[187] Z. Zhao, G. Li, Y. Han, et al., “Circular RNA ZNF609 Enhances Proliferation and Glycolysis During Glioma Progression by miR-378b/SLC2A1 Axis,” Aging 13, no. 17 (2021): 21122–21133.

[188] P. Xu, Y. Li, H. Zhang, et al., “MicroRNA-340 Mediates Metabolic Shift in Oral Squamous Cell Carcinoma by Targeting Glucose Transporter-1;” Journal of Oral and Maxillofacial Surgery 74, no. 4 (2016): 844–850.

[189] T. Matsumoto, S. Jimi, K. Migita, et al., “Inhibition of Glucose Transporter 1 Induces Apoptosis and Sensitizes Multiple Myeloma Cells to Conventional Chemotherapeutic Agents,” Leukemia Research 41 (2016): 103–110.

[190] X. Wang, Q. Yang, and Y. Wu, “Novel Insights Into the circ_0003489/Let-7b-5p/GLUT1 Axis and Its Possible Role in Multiple Myeloma,” Transplant Immunology 88 (2025): 102165.

[191] T. Liu, R. J. Kishton, A. N. Macintyre, et al., “Glucose Transporter 1-Mediated Glucose Uptake Is Limiting for B-Cell Acute Lymphoblastic Leukemia Anabolic Metabolism and Resistance to Apoptosis,” Cell Death & Disease 5, no. 10 (2014): e1470.

[192] K. Tilekar, N. Upadhyay, J. D. Hess, et al., “Structure Guided Design and Synthesis of Furyl Thiazolidinedione Derivatives as Inhibitors of GLUT 1 and GLUT 4, and Evaluation of Their Anti-Leukemic Potential,” European Journal of Medicinal Chemistry 202 (2020): 112603.

[193] N. Shen, Y. Wang, X. Sun, et al., “Expression of Hypoxia-Inducible Factor 1α, Glucose Transporter 1, and Hexokinase 2 in Primary Central Nervous System Lymphoma and the Correlation With the Biological Behaviors,” Brain and Behavior 10, no. 8 (2020): e01718.

[194] W. L. Huang, T. Abudureheman, J. Xia, et al., “CDK9 Inhibitor Induces the Apoptosis of B-Cell Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolytic Metabolism,” Frontiers in Cell and Developmental Biology 9 (2021): 641271.

[195] C. C. Liu, H. Wang, W. D. Wang, et al., “ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia,” Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 46, no. 4 (2018): 1525–1535.

[196] Y. Shi, I. S. Kotchetkov, A. Dobrin, et al., “GLUT1 Overexpression Enhances CAR T Cell Metabolic Fitness and Anti-Tumor Efficacy,” Molecular Therapy 32, no. 7 (2024): 2393–2405.

[197] A. Rai, D. W. Greening, M. Chen, et al., “Exosomes Derived From Human Primary and Metastatic Colorectal Cancer Cells Contribute to Functional Heterogeneity of Activated Fibroblasts by Reprogramming Their Proteome,” Proteomics 19, no. 8 (2019): e1800148.

[198] M. I. Koukourakis, D. Kalamida, A. G. Mitrakas, et al., “Metabolic Cooperation Between Co-Cultured Lung Cancer Cells and Lung Fibroblasts,” Laboratory Investigation; a Journal of Technical Methods and Pathology 97, no. 11 (2017): 1321–1331.

[199] M. T. Broz, E. Y. Ko, K. Ishaya, et al., “Metabolic Targeting of Cancer Associated Fibroblasts Overcomes T-cell Exclusion and Chemoresistance in Soft-tissue Sarcomas,” Nature Communications 15, no. 1 (2024): 2498.

[200] X. Wang, Y. Wang, B. Bai, et al., “PKMζ, a Brain-specific PKCζ Isoform, Is Required for Glycolysis and Myofibroblastic Activation of Hepatic Stellate Cells,” Cellular and Molecular Gastroenterology and Hepatology 19, no. 3 (2025): 101429.

[201] A. Shaha, Y. Wang, X. Wang, et al., “CMTM6 Mediates the Warburg Effect and Promotes the Liver Metastasis of Colorectal Cancer,” Experimental & Molecular Medicine 56, no. 9 (2024): 2002–2015.

[202] H. Ji, X. Song, X. Lv, et al., “[(68)Ga]FAPI PET for Imaging and Treatment Monitoring in a Preclinical Model of Pulmonary Fibrosis: Comparison to [(18)F]FDG PET and CT,” Pharmaceuticals (Basel, Switzerland) 17, no. 6 (2024): 726.

[203] Y. Wu, W. Chen, J. Deng, et al., “Cancer-Associated Fibroblast-Derived Extracellular Vesicles Loaded With GLUT1 Inhibitor Synergize Anti-PD-L1 to Suppress Tumor Growth via Degrading Matrix Stiffness and Remodeling Tumor Microenvironment,” Journal of Controlled Release 385 (2025): 113998.

[204] W. Zhang, G. Bouchard, A. Yu, et al., “GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma,” Cancer Research 78, no. 13 (2018): 3445–3457.

[205] J. Xia, S. Zhang, R. Zhang, et al., “Targeting Therapy and Tumor Microenvironment Remodeling of Triple-Negative Breast Cancer by Ginsenoside Rg3 Based Liposomes,” Journal of Nanobiotechnology 20, no. 1 (2022): 414.

[206] I. Pasanen, S. Lehtonen, R. Sormunen, et al., “Breast Cancer Carcinoma-associated Fibroblasts Differ From Breast Fibroblasts in Immunological and Extracellular Matrix Regulating Pathways,” Experimental Cell Research 344, no. 1 (2016): 53–66.

[207] D. Zhang, J. Li, X. Xu, et al., “CAF-derived GLUT1 and Its Role in Modulating Ovarian Cancer Progression: A Multi-Dimensional Analysis of the Tumor Microenvironment,” Communications Biology 8, no. 1 (2025): 1020.

[208] N. M de-Brito, J. Duncan-Moretti, H. C da-Costa, et al., “Aerobic Glycolysis Is a Metabolic Requirement to Maintain the M2-Like Polarization of Tumor-Associated Macrophages,” Biochimica et Biophysica Acta Molecular Cell Research 1867, no. 2 (2020): 118604.

[209] H. Li, R. Zhu, X. Liu, et al., “Siglec-15 Regulates the Inflammatory Response and Polarization of Tumor-Associated Macrophages in Pancreatic Cancer by Inhibiting the cGAS-STING Signaling Pathway,” Oxidative Medicine and Cellular Longevity 2022 (2022): 3341038.

[210] R. X. Sun, Y. F. Liu, Y. S. Sun, et al., “GPC3-targeted CAR-T Cells Expressing GLUT1 or AGK Exhibit Enhanced Antitumor Activity Against Hepatocellular Carcinoma,” Acta Pharmacologica Sinica 45, no. 9 (2024): 1937–1950.

[211] C. Garlapati, S. Joshi, R. C. Turaga, et al., “Monoethanolamine-Induced Glucose Deprivation Promotes Apoptosis Through Metabolic Rewiring in Prostate Cancer,” Theranostics 11, no. 18 (2021): 9089–9106.

[212] C. Y. Kuo, Y. C. Hsu, M. J. Chen, et al., “Glucose Transporter 1 Inhibitors Induce Autophagy and Synergize with Lenvatinib in Thyroid Cancer Cells,” Head & Neck 47, no. 2 (2025): 615–624.

[213] P. Ojeda, A. Pérez, L. Ojeda, et al., “Noncompetitive Blocking of human GLUT1 Hexose Transporter by Methylxanthines Reveals an Exofacial Regulatory Binding Site,” American Journal of Physiology Cell Physiology 303, no. 5 (2012): C530–C539.

[214] N. S. Ramadan, N. H. El-Sayed, S. A. El-Toumy, et al., “Anti-Obesity Evaluation of Averrhoa carambola L. Leaves and Assessment of Its Polyphenols as Potential α-Glucosidase Inhibitors,” Molecules (Basel, Switzerland) 27, no. 16 (2022): 5159.

[215] T. Shima, K. Taniguchi, Y. Tokumaru, et al., “Glucose Transporter-1 Inhibition Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumor Cells,” Oncology Reports 47, no. 1 (2022): 7.

[216] F. Zhao, J. Ming, Y. Zhou, et al., “Inhibition of Glut1 by WZB117 Sensitizes Radioresistant Breast Cancer Cells to Irradiation,” Cancer Chemotherapy and Pharmacology 77, no. 5 (2016): 963–972.

[217] Y. Peng, S. N. Xing, H. Y. Tang, et al., “Influence of Glucose Transporter 1 Activity Inhibition on Neuroblastoma in Vitro,” Gene 689 (2019): 11–17.

[218] R. S. Zhang, Z. K. Li, J. Liu, et al., “WZB117 enhanced the Anti-Tumor Effect of Apatinib Against Melanoma via Blocking STAT3/PKM2 Axis,” Frontiers in Pharmacology 13 (2022): 976117.

[219] Z. A. Miller, S. Muthuswami, A. Mueller, et al., “GLUT1 Inhibitor BAY-876 Induces Apoptosis and Enhances Anti-Cancer Effects of Bitter Receptor Agonists in Head and Neck Squamous Carcinoma Cells,” Cell Death Discovery 10, no. 1 (2024): 339.

[220] D. J. Adams, D. Ito, M. G. Rees, et al., “NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes,” ACS Chemical Biology 9, no. 10 (2014): 2247–2254.

[221] D. Kraus, J. Reckenbeil, N. Veit, et al., “Targeting Glucose Transport and the NAD Pathway in Tumor Cells With STF-31: A Re-Evaluation,” Cellular Oncology (Dordrecht, Netherlands) 41, no. 5 (2018): 485–494.

[222] S. Hoshi, S. Meguro, H. Imai, et al., “Upregulation of Glucocorticoid Receptor-Mediated Glucose Transporter 4 in Enzalutamide-Resistant Prostate Cancer,” Cancer Science 112, no. 5 (2021): 1899–1910.

[223] Y. D. Wang, S. J. Li, and J. X. Liao, “Inhibition of Glucose Transporter 1 (GLUT1) Chemosensitized Head and Neck Cancer Cells to Cisplatin,” Technology in Cancer Research & Treatment 12, no. 6 (2013): 525–535.

[224] C. Xintaropoulou, C. Ward, A. Wise, et al., “Expression of Glycolytic Enzymes in Ovarian Cancers and Evaluation of the Glycolytic Pathway as a Strategy for Ovarian Cancer Treatment,” BMC Cancer 18, no. 1 (2018): 636.

[225] L. Y. Yu, P. W. Shueng, H. C. Chiu, et al., “Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy,” ACS Nano 17, no. 14 (2023): 13158–13175.

[226] S. Jagdale, M. Narwade, A. Sheikh, et al., “GLUT1 Transporter-Facilitated Solid Lipid Nanoparticles Loaded With Anti-Cancer Therapeutics for Ovarian Cancer Targeting,” International Journal of Pharmaceutics 637 (2023): 122894.

[227] C. Zhang, Z. Liu, F. Wang, et al., “Nanomicelles for GLUT1-Targeting Hepatocellular Carcinoma Therapy Based on NADPH Depletion,” Drug Delivery 30, no. 1 (2023): 2162160.

[228] M. Woźniak, G. Pastuch-Gawołek, S. Makuch, et al., “In Vitro and In Vivo Efficacy of a Novel Glucose-Methotrexate Conjugate in Targeted Cancer Treatment,” International Journal of Molecular Sciences 22, no. 4 (2021): 1748.

[229] S. Wu, K. Zhang, Y. Liang, et al., “Nano-Enabled Tumor Systematic Energy Exhaustion via Zinc (II) Interference Mediated Glycolysis Inhibition and Specific GLUT1 Depletion,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 9, no. 7 (2022): e2103534.

[230] X. Zhang, H. Tian, Y. Chen, et al., “A Metal-organic Nanoframework for Efficient Colorectal Cancer Immunotherapy by the cGAS-STING Pathway Activation and Immune Checkpoint Blockade,” Journal of Nanobiotechnology 22, no. 1 (2024): 592.

[231] H. Geng, L. Chen, S. Lv, et al., “Photochemically Controlled Release of the Glucose Transporter 1 Inhibitor for Glucose Deprivation Responses and Cancer Suppression Research,” Journal of Proteome Research 23, no. 2 (2024): 653–662.

[232] K. Wang, L. Li, G. Liang, et al., “Sonodynamic Activated Nanoparticles With Glut1 Inhibitor and Cystine-containing Polymer Stimulate Disulfidptosis for Improved Immunotherapy in Bladder Cancer,” Biomaterials 319 (2025): 123178.

[233] T. Li, D. Xu, Z. Ruan, et al., “Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade,” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 11, no. 18 (2024): e2310163.

[234] K. Wang, X. Dai, A. Yu, et al., “Peptide-based PROTAC Degrader of FOXM1 Suppresses Cancer and Decreases GLUT1 and PD-L1 Expression,” Journal of Experimental & Clinical Cancer Research: CR 41, no. 1 (2022): 289.

[235] L. Liu, W. Xiao, and Z. Yang, “Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomal miR-214-3p Regulates the Progression of Gallbladder Cancer by Regulating ACLY/GLUT1,” Advances in Clinical and Experimental Medicine University 33, no. 5 (2024): 499–510.

[236] J. Luo, Q. Gao, K. Tan, et al., “Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation,” Journal of the American Chemical Society 146, no. 26 (2024): 17728–17737.

[237] H. Yang, M. Z. Zhang, H. W. Sun, et al., “A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma,” Frontiers in Oncology 11 (2021): 783194.

[238] Y. Zeng, Y. Zheng, T. Zhang, et al., “Identification of a Subtype-Selective Allosteric Inhibitor of GluN1/GluN3 NMDA Receptors,” Frontiers in Pharmacology 13 (2022): 888308.

[239] S. Tahk, K. Virumae, K. Anton, et al., “Development of Therapeutic Antibodies Targeting the GLUT-1 Transporter to Restrict Cancer Cell Growth,” Cancer Research 84, no. 6 _Supplement (2024): 1876.

[240] Z.-Y. Xing, Z. Lin, J. Gu, et al., “Effect and Mechanism of STF-31 Combined With Cisplatin in Overcoming Platinum Resistance in Ovarian Cancer,” Journal of Clinical Oncology 43, no. 16 _suppl (2025): e17594.

[241] S. Dyshlovoy, T. Busenbender, D. Pelageev, et al., “Abstract 5741: 6-((1,4-Naphthoquinone-2-yl)methyl)Thio-Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer,” Cancer Research 85, no. 8 _Supplement_1 (2025): 5741.

[242] C. J. Landis, S. Zhang, G. A. Benavides, et al., “Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro,” ACS Chemical Biology 13, no. 8 (2018): 2048–2057.

[243] X. Chen, Y. Zhao, C. He, et al., “Identification of a Novel GLUT1 Inhibitor With in Vitro and in Vivo Anti-Tumor Activity,” International Journal of Biological Macromolecules 216 (2022): 768–778.

[244] Y. Chen, J. Joo, J. M. Chu, et al., “Downregulation of the Glucose Transporter GLUT 1 in the Cerebral Microvasculature Contributes to Postoperative Neurocognitive Disorders in Aged Mice,” Journal of Neuroinflammation 20, no. 1 (2023): 237.

[245] T. S. Pearson, C. Akman, V. J. Hinton, et al., “Phenotypic Spectrum of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS),” Current Neurology and Neuroscience Reports 13, no. 4 (2013): 342.

[246] F. Fontana, G. Giannitti, S. Marchesi, et al., “The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer,” International Journal of Biological Sciences 20, no. 8 (2024): 3113–3125.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.